Spots Global Cancer Trial Database for pegylated liposomal doxorubicin hydrochloride
Every month we try and update this database with for pegylated liposomal doxorubicin hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer | NCT00004236 | Esophageal Canc... Gastric Cancer | pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma | NCT00101010 | Lymphoma | Filgrastim Pegfilgrastim Rituximab Cyclophosphamid... Pegylated lipos... Prednisone Vincristine Sul... | 61 Years - | M.D. Anderson Cancer Center | |
| Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma | NCT00002985 | Sarcoma | daunorubicin hy... pegylated lipos... | - | Roswell Park Cancer Institute | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02839707 | Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... | Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02446600 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... | Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003385 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pegylated lipos... | - | GOG Foundation | |
| Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | NCT00003135 | Breast Cancer Cervical Cancer Endometrial Can... Ovarian Cancer | fluorouracil pegylated lipos... hyperthermia tr... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | NCT05711615 | Metastatic Leio... Metastatic Sarc... Metastatic Soft... Unresectable Le... Unresectable Sa... Unresectable So... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pegylated Lipos... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers | NCT00003207 | Sarcoma Unspecified Adu... | pegylated lipos... PSC 833 | 18 Years - | Washington University School of Medicine | |
| Chemotherapy in Treating Patients With Sarcoma of the Uterus | NCT00005643 | Endometrial Can... Sarcoma | pegylated lipos... | 21 Years - | GOG Foundation | |
| Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00244985 | Lymphoma | rituximab pegylated lipos... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | NCT03591744 | Plasma Cell Leu... | Bortezomib Daratumumab Dexamethasone Lenalidomide Pegylated Lipos... | 18 Years - | City of Hope Medical Center | |
| Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00742404 | Multiple Myelom... | bortezomib dexamethasone pegylated lipos... protein analysi... immunologic tec... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer | NCT00960336 | Breast Cancer | pegylated lipos... | 70 Years - | ARCAGY/ GINECO GROUP | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | NCT01294293 | Malignant Ovari... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... | TLR8 Agonist VT... Diagnostic Labo... Pharmacological... Pegylated Lipos... Paclitaxel | 18 Years - | GOG Foundation | |
| Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer | NCT00005980 | Breast Cancer | pegylated lipos... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | NCT04092270 | Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima... | Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer | NCT00005861 | Endometrial Can... | pegylated lipos... | - | GOG Foundation | |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | NCT03907475 | Malignant Solid... | Biopsy Biospecimen Col... Capecitabine Carboplatin Computed Tomogr... Durvalumab Echocardiograph... Gemcitabine Hyd... Nab-paclitaxel Paclitaxel Pegylated Lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | NCT00334932 | Multiple Myelom... | bortezomib melphalan pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | NCT03203525 | Advanced Malign... Colorectal Carc... Metastatic Mali... Refractory Mali... | Bevacizumab Fluorouracil Leucovorin Oxaliplatin Pegylated Lipos... Temsirolimus Tumor Treating ... | 18 Years - | M.D. Anderson Cancer Center | |
| S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer | NCT00043082 | Ovarian Cancer Peritoneal Cavi... | carboplatin pegylated lipos... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | NCT05295589 | Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... | Computed Tomogr... Copanlisib Hydr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer | NCT00006825 | Breast Cancer | trastuzumab pegylated lipos... | 18 Years - | NYU Langone Health | |
| Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | NCT00020449 | Sarcoma | recombinant int... paclitaxel pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma | NCT00002985 | Sarcoma | daunorubicin hy... pegylated lipos... | - | Roswell Park Cancer Institute | |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | NCT05295589 | Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... | Computed Tomogr... Copanlisib Hydr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin | NCT00004030 | Unspecified Adu... | VX-853 pegylated lipos... | 18 Years - | Georgetown University | |
| Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer | NCT00296010 | Breast Cancer | cyclophosphamid... methotrexate pegylated lipos... adjuvant therap... radiation thera... | 66 Years - 120 Years | ETOP IBCSG Partners Foundation | |
| A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) | NCT00727961 | Ovarian Neoplas... | Pegylated Lipos... | 18 Years - | Merck Sharp & Dohme LLC | |
| Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | NCT00003334 | Endometrial Can... Fallopian Tube ... Ovarian Cancer Sarcoma | paclitaxel pegylated lipos... | - 120 Years | NYU Langone Health | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00337194 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular S... Recurrent Adult... | monoclonal anti... placebo vinorelbine tar... pegylated lipos... gemcitabine hyd... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer | NCT00470067 | Endometrial Can... | carboplatin pegylated lipos... | 18 Years - | Roswell Park Cancer Institute | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer | NCT00004236 | Esophageal Canc... Gastric Cancer | pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer | NCT00003296 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | filgrastim pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Multiple Myeloma | NCT00003493 | Multiple Myelom... | dexamethasone pegylated lipos... vincristine sul... | - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | NCT00032162 | Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Sarcoma | carboplatin pegylated lipos... | 18 Years - | AGO Study Group | |
| Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma | NCT00101010 | Lymphoma | Filgrastim Pegfilgrastim Rituximab Cyclophosphamid... Pegylated lipos... Prednisone Vincristine Sul... | 61 Years - | M.D. Anderson Cancer Center | |
| Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | NCT00020449 | Sarcoma | recombinant int... paclitaxel pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | NCT00851552 | Lymphoma | rituximab bortezomib pegylated lipos... gene expression... polymerase chai... polymorphism an... proteomic profi... flow cytometry laboratory biom... | 18 Years - | Roswell Park Cancer Institute | |
| Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | NCT00849251 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | cyclophosphamid... pegylated lipos... bortezomib dexamethasone | 18 Years - | University of Washington | |
| Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00003380 | Fallopian Tube ... Ovarian Cancer Primary Periton... | etoposide pegylated lipos... | - | GOG Foundation | |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | NCT00006372 | Unspecified Adu... | gemcitabine hyd... pegylated lipos... vinorelbine dit... | 18 Years - | Case Comprehensive Cancer Center | |
| Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | NCT00524459 | Breast Cancer | docetaxel pegylated lipos... conventional su... neoadjuvant the... | - 64 Years | Roswell Park Cancer Institute | |
| Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer | NCT00005980 | Breast Cancer | pegylated lipos... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | NCT00003135 | Breast Cancer Cervical Cancer Endometrial Can... Ovarian Cancer | fluorouracil pegylated lipos... hyperthermia tr... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | NCT02456857 | Invasive Breast... Triple-Negative... | Bevacizumab Everolimus Laboratory Biom... Pegylated Lipos... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | NCT00003334 | Endometrial Can... Fallopian Tube ... Ovarian Cancer Sarcoma | paclitaxel pegylated lipos... | - 120 Years | NYU Langone Health | |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | NCT00006372 | Unspecified Adu... | gemcitabine hyd... pegylated lipos... vinorelbine dit... | 18 Years - | Case Comprehensive Cancer Center | |
| EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT01489371 | Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... PEG-PEI-cholest... Pegylated Lipos... | 18 Years - | GOG Foundation | |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | NCT02502266 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Cediranib Cediranib Malea... Computed Tomogr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Questionnaire A... Topotecan Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer | NCT00992706 | Breast Cancer Palmar-plantar ... | antiperspirant ... pegylated lipos... | 18 Years - 120 Years | Swiss Group for Clinical Cancer Research | |
| Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer | NCT00061867 | Prostate Cancer | pegylated lipos... hyperthermia tr... | 40 Years - | National Cancer Institute (NCI) | |
| EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT01489371 | Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... PEG-PEI-cholest... Pegylated Lipos... | 18 Years - | GOG Foundation | |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01673217 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | decitabine NY-ESO-1 peptid... pegylated lipos... sargramostim incomplete Freu... immunohistochem... liquid chromato... mass spectromet... reverse transcr... laboratory biom... DNA methylation... enzyme-linked i... | 18 Years - | Roswell Park Cancer Institute | |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT01459380 | Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... | Bevacizumab Carboplatin Laboratory Biom... Pegylated Lipos... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | NCT02315196 | Estrogen Recept... HER2-negative B... Progesterone Re... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | pegylated lipos... epirubicin hydr... carboplatin therapeutic con... paclitaxel laboratory biom... quality-of-life... | 18 Years - | Rutgers, The State University of New Jersey | |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | NCT02315196 | Estrogen Recept... HER2-negative B... Progesterone Re... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | pegylated lipos... epirubicin hydr... carboplatin therapeutic con... paclitaxel laboratory biom... quality-of-life... | 18 Years - | Rutgers, The State University of New Jersey | |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | NCT03907475 | Malignant Solid... | Biopsy Biospecimen Col... Capecitabine Carboplatin Computed Tomogr... Durvalumab Echocardiograph... Gemcitabine Hyd... Nab-paclitaxel Paclitaxel Pegylated Lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00006235 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin pegylated lipos... | - | GOG Foundation | |
| Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma | NCT00003350 | AIDS-related Ka... | paclitaxel pegylated lipos... laboratory biom... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01673217 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | decitabine NY-ESO-1 peptid... pegylated lipos... sargramostim incomplete Freu... immunohistochem... liquid chromato... mass spectromet... reverse transcr... laboratory biom... DNA methylation... enzyme-linked i... | 18 Years - | Roswell Park Cancer Institute | |
| Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer | NCT00004925 | Breast Cancer | trastuzumab pegylated lipos... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | NCT03203525 | Advanced Malign... Colorectal Carc... Metastatic Mali... Refractory Mali... | Bevacizumab Fluorouracil Leucovorin Oxaliplatin Pegylated Lipos... Temsirolimus Tumor Treating ... | 18 Years - | M.D. Anderson Cancer Center | |
| VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin | NCT00004030 | Unspecified Adu... | VX-853 pegylated lipos... | 18 Years - | Georgetown University | |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT01459380 | Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... | Bevacizumab Carboplatin Laboratory Biom... Pegylated Lipos... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | NCT00849251 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | cyclophosphamid... pegylated lipos... bortezomib dexamethasone | 18 Years - | University of Washington | |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma | NCT05711628 | Recurrent Class... Refractory Clas... | Autologous Hema... Bendamustine Brentuximab Ved... Carboplatin Computed Tomogr... Etoposide Gemcitabine Ifosfamide Pegylated Lipos... Pembrolizumab Positron Emissi... Radiation Thera... Transplant Cond... Vinorelbine | 5 Years - 75 Years | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer | NCT00027989 | Breast Cancer | gemcitabine hyd... pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery | NCT00671476 | Breast Cancer | pegylated lipos... DNA methylation... TdT-mediated dU... fluorescence in... loss of heteroz... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... breast duct lav... neoadjuvant the... therapeutic con... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix | NCT00030472 | Cervical Cancer | pegylated lipos... | - | GOG Foundation | |
| Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02312245 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Bevacizumab Gemcitabine Hyd... Paclitaxel Pegylated Lipos... Topotecan Hydro... | 18 Years - | Mayo Clinic | |
| Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer | NCT00006825 | Breast Cancer | trastuzumab pegylated lipos... | 18 Years - | NYU Langone Health | |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | NCT00006372 | Unspecified Adu... | gemcitabine hyd... pegylated lipos... vinorelbine dit... | 18 Years - | Case Comprehensive Cancer Center | |
| Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma | NCT00030784 | Sarcoma | ifosfamide pegylated lipos... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00006235 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin pegylated lipos... | - | GOG Foundation | |
| Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer | NCT00004888 | Recurrent Breas... Stage IV Breast... | pegylated lipos... docetaxel trastuzumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer | NCT00005861 | Endometrial Can... | pegylated lipos... | - | GOG Foundation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
